We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 20, 2009
Last Update Posted: February 2, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Yonsei University
For diagnosis of active tuberculosis, interferon-γ release assay based mycobacterium tuberculosis specific antigen may show higher sensitivity than tuberculin skin test in immunocompromised patients. Therefore, interferon-γ release assay have a role as a rapid diagnostic adjunctive methods for active tuberculosis in immunocompromised patients.


Study Type: Observational

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Enrollment: 140
Study Start Date: July 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
immunocompromised group
non-immunocompromised group


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
suspicious of tuberculosis, immunocompromised patients such cancer patients on chemotherapy, transplantation patients, patients with immunosuppressant

Inclusion Criteria:

  • Patient suspicious of active tuberculosis with immunocompromised condition
  • Immunocompromised condition patients with

    1. solid cancer with chemotherapy
    2. hematologic malignancy
    3. organ transplantation
    4. immunosuppressant
    5. ESRD on renal replacement therapy
    6. diabetes
    7. advanced liver cirrhosis

Exclusion Criteria:

  • Patients with

    1. less than 20 years
    2. who don't agree the participation of study
    3. hypersensitivity history to tuberculin
    4. pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00962676

Korea, Republic of
Yonsei Univ.
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
  More Information

Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT00962676     History of Changes
Other Study ID Numbers: 4-2009-0129
First Submitted: August 19, 2009
First Posted: August 20, 2009
Last Update Posted: February 2, 2012
Last Verified: January 2012

Keywords provided by Yonsei University:
suspicious of tuberculosis
immunocompromised patients

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections